X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2023/03/14/2627246/0/en/Travere-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2023/03/14/2627211/0/en/Travere-Therapeutics-to-Present-Abstracts-at-the-Society-for-Inherited-Metabolic-Disorders-44th-Annual-Meeting-and-the-American-College-of-Medical-Genetics-and-Genomics-Annual-Clin.html
https://www.globenewswire.com/news-release/2023/03/03/2620543/0/en/Travere-Therapeutics-Announces-Completion-of-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants-and-Exercise-in-Full-of-Underwriters-Option-to-Purchase-Additional-Shares.html
https://www.globenewswire.com/news-release/2023/03/01/2617801/0/en/Travere-Therapeutics-Announces-Pricing-of-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html
https://www.globenewswire.com/news-release/2023/02/27/2616461/0/en/Travere-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html
https://www.globenewswire.com/news-release/2023/02/23/2614781/0/en/Travere-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results.html
https://www.fiercepharma.com/marketing/travere-fda-approval-bristol-myers-castoff-unique-drug-rare-kidney-disease
https://www.globenewswire.com/news-release/2023/02/16/2610276/0/en/Travere-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2022-Financial-Results.html
https://www.globenewswire.com/news-release/2023/02/13/2607163/0/en/Travere-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2023/02/08/2604488/0/en/Travere-Therapeutics-to-Present-at-Upcoming-Investor-Conferences.html
Market Place
Share 
